This landmark 1988 paper by Wozney et al. identifies and clones three distinct human bone morphogenetic proteins from a purified bovine bone extract. It asks: which molecular components of the extract are responsible for osteoinduction, and can recombinant versions replicate that activity? The answer established the molecular foundation for BMP-based bone repair.
Getting recombinant BMP-2 (rhBMP-2, dibotermin alfa) approved for lumbar spinal fusion and open tibial fractures traces directly to this paper. Wozney's group showed that osteoinduction requires specific BMP molecules, not crude extracts, and that recombinant production is both feasible and sufficient to reproduce the activity.
When you use rhBMP-2 in a posterolateral fusion or apply it to a tibial nonunion, the rationale is grounded here: a defined recombinant protein delivered in a carrier can substitute for the complex signaling normally supplied by bone matrix.
The finding that TGF-β does NOT induce bone in vivo despite its presence in bone matrix matters clinically — it means osteoinductive capacity cannot be assumed from structural family membership alone.
The homodimer/heterodimer biology introduced here also explains why BMP dosing is non-trivial: subunit configuration modulates activity, which is why supraphysiologic doses of rhBMP-2 carry risks (ectopic ossification, osteolysis) that were not fully anticipated from the early in vivo cartilage assays.
This landmark 1988 paper by Wozney et al. identifies and clones three distinct human bone morphogenetic proteins from a purified bovine bone extract. It asks: which molecular components of the extract are responsible for osteoinduction, and can recombinant versions replicate that activity? The answer established the molecular foundation for BMP-based bone repair.
Getting recombinant BMP-2 (rhBMP-2, dibotermin alfa) approved for lumbar spinal fusion and open tibial fractures traces directly to this paper. Wozney's group showed that osteoinduction requires specific BMP molecules, not crude extracts, and that recombinant production is both feasible and sufficient to reproduce the activity.
When you use rhBMP-2 in a posterolateral fusion or apply it to a tibial nonunion, the rationale is grounded here: a defined recombinant protein delivered in a carrier can substitute for the complex signaling normally supplied by bone matrix.
The finding that TGF-β does NOT induce bone in vivo despite its presence in bone matrix matters clinically — it means osteoinductive capacity cannot be assumed from structural family membership alone.
The homodimer/heterodimer biology introduced here also explains why BMP dosing is non-trivial: subunit configuration modulates activity, which is why supraphysiologic doses of rhBMP-2 carry risks (ectopic ossification, osteolysis) that were not fully anticipated from the early in vivo cartilage assays.